RAS mutations in human cancers: Roles in precision medicine

被引:96
作者
Murugan, Avaniyapuram Kannan [1 ,3 ]
Grieco, Michele [2 ]
Tsuchida, Nobuo [1 ]
机构
[1] Tokyo Med & Dent Univ, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan
[2] Seconda Univ Napoli, DiSTABiF, Dipartimento Sci & Tecnol Ambientali Biol & Farma, Via Vivaldi 43, I-81100 Caserta, Italy
[3] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, POB 3354,Res Ctr MBC 03, Riyadh 11211, Saudi Arabia
关键词
Mutation; Precision medicine; Oncogene; HRAS; KRAS; NRAS; Cancer; Personalized medicine; GROWTH-FACTOR RECEPTOR; K-RAS; SARCOMA-VIRUS; TRANSFORMING GENE; HUMAN BLADDER; CELL-LINES; MOLECULAR-CLONING; LUNG-CARCINOMA; KRAS MUTATION; MALIGNANT ACTIVATION;
D O I
10.1016/j.semcancer.2019.06.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ras proteins play a crucial role as a central component of the cellular networks controlling a variety of signaling pathways that regulate growth, proliferation, survival, differentiation, adhesion, cytoskeletal rearrangements and motility of a cell. Almost, 4 decades passed since Ras research was started and ras genes were originally discovered as retroviral oncogenes. Later on, mutations of the human RAS genes were linked to tumorigenesis. Genetic analyses found that RAS is one of the most deregulated oncogenes in human cancers. In this review, we summarize the pioneering works which allowed the discovery of RAS oncogenes, the finding of frequent mutations of RAS in various human cancers, the role of these mutations in tumorigenesis and mutation-activated signaling networks. We further describe the importance of RAS mutations in personalized or precision medicine particularly in molecular targeted therapy, as well as their use as diagnostic and prognostic markers as therapeutic determinants in human cancers.
引用
收藏
页码:23 / 35
页数:13
相关论文
共 145 条
[1]   Regulating the regulator: post-translational modification of RAS [J].
Ahearn, Ian M. ;
Haigis, Kevin ;
Bar-Sagi, Dafna ;
Philips, Mark R. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (01) :39-51
[2]   Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer [J].
Alguacil, J ;
Porta, M ;
Malats, N ;
Kauppinen, T ;
Kogevinas, M ;
Benavides, FG ;
Partanen, T ;
Carrato, A .
CARCINOGENESIS, 2002, 23 (01) :101-106
[3]   American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].
Allegra, Carmen J. ;
Jessup, J. Milburn ;
Somerfield, Mark R. ;
Hamilton, Stanley R. ;
Hammond, Elizabeth H. ;
Hayes, Daniel F. ;
McAllister, Pamela K. ;
Morton, Roscoe F. ;
Schilsky, Richard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096
[4]   MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].
ALMOGUERA, C ;
SHIBATA, D ;
FORRESTER, K ;
MARTIN, J ;
ARNHEIM, N ;
PERUCHO, M .
CELL, 1988, 53 (04) :549-554
[5]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[6]   K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives [J].
Asati, Vivek ;
Mahapatra, Debarshi Kar ;
Bharti, Sanjay Kumar .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 125 :299-314
[7]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[8]   Dampening oncogenic RAS signaling [J].
Bivona, Trever G. .
SCIENCE, 2019, 363 (6433) :1280-1281
[9]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[10]  
BOS JL, 1989, CANCER RES, V49, P4682